Daiichi Sankyo Company Limited operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Daiichi Sankyo Company Limited with three other
companies in this sector in Japan:
Astellas Pharma Incorporated
sales of 1.37 trillion Japanese Yen [US$13.22 billion]
of which 57%
Mitsubishi Tanabe Pharma Corp
(431.70 billion Japanese Yen [US$4.16 billion]
Eisai Company Limited
(547.92 billion Japanese Yen [US$5.28 billion]
of which 49%
was Pharmaceutical Business -Japan).
Daiichi Sankyo Company Limited reported sales of ¥986.45 billion (US$9.50 billion)
March of 2016.
increase of 7.3%
versus 2015, when the company's sales were ¥919.37 billion.
Despite this increase, sales are still
below the level achieved in 2014, when Daiichi Sankyo Company Limited
reported sales of ¥1.12 trillion.
The sales level in 2016 was fairly close to the level five years ago: in 2011, Daiichi Sankyo Company Limited had sales
of ¥967.37 billion.
Sales of Healthcare Products saw an increase
11.6% in 2016, from
¥47.82 billion to ¥53.37 billion.
Not all segments of Daiichi Sankyo Company Limited experienced an increase in sales in 2016:
sales of Other fell 0.5% to ¥2.76 billion.
(However, this segment's sales were only a very small portion of the company's overall sales).